Benzinga | Apr 12, 2021 07:03AM EDT

Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(r) antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the presentation of a poster highlighting preclinical BP1002 data at the 2021 American Association for Cancer Research (AACR) Annual Meeting.



The poster, titled "The combination of liposomal Bcl-2 antisense oligonucleotide (BP1002) with decitabine is efficacious in venetoclax-resistant cells," was presented virtually by Dr. Maria Gagliardi, Research Scientist at Bio-Path Holdings.